NCT00995969 - CT 327 in the Treatment of Psoriasis Vulgaris | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Psoriasis

Interventions

DRUG

placebo

1.0 g (w/w) placebo cream applied to both target lesions twice daily

DRUG

CT 327

1.0 g CT 327 cream will be applied to one target lesion twice daily and 1.0 g placebo cream will be applied to the remaining target lesion twice daily

Trial Locations (12)

3010

Inselspital, Bern

27103

Piedmont Medical Research, LLC, Winston-Salem

28209

Metrolina Medical Research, Charlotte

28401

New Hanover Medical Research, Wilmington

37040

Premier Medical Group, P.C., Clarksville

37604

East Tennessee Medical Research, Johnson City

CH-4031

University Hospital, Basel

CH-9007

Kantonsspital, Sankt Gallen

CH-8091

University Hospital, Zurich

B15 2SQ

Synexus Midlands, Birmingham

G81 2DR

Synexus Scotland, Clydebank

CF14 5GJ

Synexus Wales, Cardiff